Insight Molecular Diagnostics Inc DEFA14A, filed May 21, 2021
Insight Molecular Diagnostics Inc. (IMDX)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A
(Rule 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
| ☐ | Preliminary Proxy Statement |
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☐ | Definitive Proxy Statement |
| ☒ | Definitive Additional Materials |
| ☐ | Soliciting Material Pursuant to §240.14a-12 |
OncoCyte Corporation
(Name of Registrant as Specified in Its Charter)
(Name of Person(s) Filing Proxy Statement if other than the Registrant)
| Payment of Filing Fee (Check the appropriate box): | |
| ☒ | No fee required. |
| ☐ | Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. |
| (1) | Title of each class of securities to which transaction applies: | |
| (2) | Aggregate number of securities to which transaction applies: | |
| (3) | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined): | |
| (4) | Proposed maximum aggregate value of transaction: | |
| (5) | Total fee paid: | |
| ☐ | Fee paid previously with preliminary materials. |
| ☐ | Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing. |
| (1) | Amount previously paid: | |
| (2) | Form, schedule or registration statement no.: | |
| (3) | Filing party: | |
| (4) | Date filed: | |
 |
15 Cushing Road |
| Irvine, CA 92618 | |
| +844.ONCOCYTE | |
| +844.662.6298 | |
| +949.409.7600 | |
| customer.service@oncocyte.com | |
| oncocyte.com |
May 21, 2021
Dear Oncocyte Shareholder,
To say 2020 was a fascinating year would be quite an understatement! As I write, the United States is in full vaccination mode from the worst pandemic in over a century and our way of life is slowly returning to what will certainly be a “New Normal”. Despite the macroenvironmental challenges of the past year, Oncocyte stayed true to our mission and has entered 2021 much stronger than we entered 2020!
2020 was a transformational year for our company with numerous milestones achieved:
| ● | DetermaRx was launched in the spring as the pandemic started, and despite the incredible headwind we encountered, we were able to onboard 82 hospitals,138 treating physicians and identified over 100 patients who were high risk for recurring Non-Small Cell Lung Cancer. | |
| ● | We acquired Insight Genetics in late January of 2020, and within 90 days we validated and launched DetermaIO™ into the pharma clinical trial market as the only precision diagnostic available that can predict which patients will have a sustained response to immune therapy. In the past six months, our increased investments in clinical studies have yielded numerous papers and abstracts that have now validated DetermaIO in Non-Small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC) and Bladder Cancer, with more on the way. We remain excited about the continued success of DetermaIO and look forward to launching the test to the clinical market in the second half of 2021 | |
| ● | In the Fall of 2020, we evaluated Chronix Biomedical’s IP and technology, including TheraSure™ CNI, as a way to enter the emerging $15B blood-based monitoring market for therapeutic response and recurrence monitoring. Our diligence led to our acquisition of Chronix in April. We expect Chronix’ CNI technology and IP will be the foundation of our entry into this exciting and very large market opportunity. We believe TheraSure™ CNI, which we plan to re-brand as DetermaCNI™, will have clinical use in monitoring a patient’s response to cancer treatment, including but not limited to immunotherapy treatment. | |
| ● | Last April, following our acquisition of Insight Genetics, we launched our Pharma Services from our newly acquired CLIA and CAP certified lab in Nashville Tennessee, giving us an east coast presence from which we are delivering a robust offering of molecular laboratory services to pharma companies and diagnostic platform providers. |
I am extremely proud of our small but dedicated team and feel incredibly fortunate to lead such an outstanding group of professionals! They weathered the challenges of working through incredibly difficult circumstances over the past year, and have met every milestone we set for ourselves, on time. In only 6 quarters, we have transitioned Oncocyte from a company with a single product focus to an emerging leader in the world of oncology diagnostics with a solid menu of novel tests. We have now accumulated the technologies we need to execute on our vision of becoming the first choice of physicians helping their patients make the major treatment decisions confronting cancer patients each day.
We appreciate the relentless support of our shareholders and stakeholders! Without you we would not be in such a strong position to fulfill our mission and deliver significant shareholder value over the coming years. The future is incredibly bright, and we look forward to sharing it with you.
Together in the fight!
Ron A. Andrews